Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: Role of human liver cytosolic aldo-keto reductases

Chemico-Biological Interactions

Volumn 147, Issue 2, 2004, Pages 129-139

  Rosemond, M Jane Cox ^a   St John Williams, Lisa ^a   Yamaguchi, Toshiro ^b   Fujishita, Toshio ^b   Walsh, John S ^a  

^a GLAXOSMITHKLINE   (United States)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

AKR; Aldo keto reductase; Carbonyl reductase; CR; HIV; HP1; Human immunodeficiency virus; Human plasma metabolite 1; Liquid scintillation counter; LSC; NAD(P)H:quinone oxidoreductase 1; NQO1; NQO2; NRH:quinone oxidoreductase 2; SDR

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; ALDEHYDE KETONE REDUCTASE; ALDOKETOREDUCTASE INHIBITOR; CARBONYL DERIVATIVE; CARBONYL REDUCTASE; CARBONYL REDUCTASE INHIBITOR; DIKETONE; DRUG METABOLITE; ENZYME INHIBITOR; FLUFENAMIC ACID; INTEGRASE INHIBITOR; MENADIONE; OXIDOREDUCTASE; PHENOLPHTHALEIN; PROTEIN; QUERCETIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOSOL; DRUG EFFECT; DRUG POTENCY; ENZYME INHIBITION; ENZYMOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; INCUBATION TIME; KINETICS; LIQUID CHROMATOGRAPHY; LIVER; LIVER CYTOSOL; MASS SPECTROMETRY; MICHAELIS CONSTANT; MICROSOME; MITOCHONDRION; RADIOCHEMISTRY; REDUCTION;

ALCOHOL OXIDOREDUCTASES; ANTI-HIV AGENTS; CARBON RADIOISOTOPES; CYTOSOL; ENZYME INHIBITORS; FURANS; HIV INTEGRASE INHIBITORS; HUMANS; LIVER; MICROSOMES, LIVER; MITOCHONDRIA, LIVER; OXIDATION-REDUCTION; TRIAZOLES;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 1542286600     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2003.12.001     Document Type: Article

References (43)

1. Fauci A.S. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science. 239:1988;617-622.
2. Rabson A.B., Martin M.A. Molecular organization of the AIDS retrovirus. Cell. 40:1985;477-480.
3. Katz R.A., Skalka A.M. The retroviral enzymes. Annu. Rev. Biochem. 63:1994;133-173.
4. De Clercq E. New developments in anti-HIV chemotherapy. Curr. Med. Chem. 8:2001;1543-1572.
5. Gulick R.M. New antiretroviral drugs. Clin. Microbiol. Infect. 9:2003;186-193.
6. Garvey E.P. Unexploited viral and host targets for the treatment of human immunodeficiency virus type I infection. Curr. Drug Target. 1:2001;107-123.
7. Neamati N. Patented small molecule inhibitors of HIV-1 integrase: a 10-year saga. Expert Opin. Ther. Patents. 12:2002;709-724.
8. Oppermann U.C.T., Maser E. Molecular and structural aspects of xenobiotic carbonyl metabolising enzymes. Role of reductases and dehydrogenases in xenobiotic phase I reactions. Toxicology. 144:2000;71-81.
9. Walsh J.S., Reese M.J., Thurmond L.M. The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes. Chem. Biol. Interact. 142:2002;135-154.
10. Atalla A., Breyer-Pfaff U., Maser E. Purification and characterization of oxidoreductases catalyzing carbonyl reduction of the tobacco-specific nitrosamine 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human liver cytosol. Xenobiotica. 30:2000;755-769.
11. Hyndman D., Bauman D.R., Heredia V.V., Penning T.M. The aldo-keto reductase superfamily homepage. Chem. Biol. Interact. 143-144:2003;621-631.
12. Miyabe Y., Amano T., Deyashiki Y., Hara A., Tsukada F. Kinetic studies of the inhibition of a human liver 3α-hydroxysteroid/dihydrodiol dehydrogenase isozyme by bile acids and anti-inflammatory drugs. Biol. Pharm. Bull. 18:1995;9-12.
13. Forrest G.L., Gonzales B. Carbonyl reductase. Chem. Biol. Interact. 129:2000;21-40.
14. Oppermann U.C.T., Filling C., Jörnvall H. Forms and functions of human SDR enzymes. Chem. Biol. Interact. 130-132:2001;699-705.
15. Persson B., Kallberg Y., Oppermann U., Jörnvall H. Coenzyme-based functional assignments of short-chain dehydrogenases/reductases (SDRs). Chem. Biol. Interact. 143-144:2003;271-278.
16. Foster C.E., Bianchet M.A., Talalay P., Faig M., Amzel M. Structures of mammalian cytosolic quinone reductases. Free Radic. Biol. Med. 29:2000;241-245.
17. Ross D., Kepa J.K., Winski S.L., Beall H.D., Anwar A., Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem. Biol. Interact. 129:2000;77-97.
18. Bianchet M.A., Foster C., Faig M., Talalay P., Amzel L.M. Structure and mechanism of cytosolic quinone reductases. Biochem. Soc. Trans. 27:1999;610-615.
19. Houston J.B., Kenworthy K.E. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab. Dispos. 28:2000;246-254.
20. Hutzler J.M., Tracy T.S. Atypical kinetic profiles in drug metabolism reactions. Drug Metab. Dispos. 30:2002;355-362.
21. Witherow L.E., Houston J.B. Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat. J. Pharmacol. Exp. Ther. 290:1999;58-65.
22. Korzekwa K.R., Krishnamachary N., Shou M., Ogai A., Parise R.A., Rettie A.E., Gonzales F.J., Tracy T.S. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry. 37:1998;4137-4147.
23. Breyer-Pfaff U., Nill K. High-affinity stereoselective reduction of the enantiomers of ketotifen and of ketonic nortriptyline metabolites by aldo-keto reductases from human liver. Biochem. Pharmacol. 59:2000;249-260.
24. Ohara H., Miyabe Y., Deyashiki Y., Matsuura K., Hara A. Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. Biochem. Pharmacol. 50:1995;221-227.
25. Maser E., Stinner B., Atalla A. Carbonyl reduction of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by cytosolic enzymes in human liver and lung. Cancer Lett. 148:2000;135-144.
26. M. Dixon, E.C. Webb, Enzymes, Academic Press, New York, 1979, pp. 332-467.
27. Hermans J.J.R., Thijssen H.H.W. Stereoselective acetonyl side chain reduction of warfarin and analogs: partial characterization of two cytosolic carbonyl reductases. Drug Metab. Dispos. 20:1992;268-274.
28. Matsuura K., Hara A., Deyashiki Y., Iwasa H., Kume T., Ishikura S., Shiraishi H., Katagiri Y. Roles of C-terminal binding domains of human dihydrodiol dehydrogenase isoforms in the binding of substrates and modulators: probing with chimaeric enzymes. Biochem. J. 336:1998;429-436.
29. Penning T.M., Burczynski M.E., Jez J.M., Lin H.K., Ma H., Moore M., Ratnam K., Palackal N. Structure-function aspects and inhibitor design of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3). Mol. Cell. Endocrinol. 171:2001;137-149.
30. Usami N., Yamamoto T., Shintani S., Higaku Y., Ishikura S., Katagiri Y., Hara A. Substrate specificity of human 3(20)α-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol. Pharm. Bull. 25:2002;441-445.
31. Deyashiki Y., Taniguchi H., Amano T., Nakayama T., Hara A., Sawada H. Structural and functional comparison of two human liver dihydrodiol dehydrogenases associated with 3α-hydroxysteroid dehydrogenase activity. Biochem. J. 282:1992;741-746.
32. Jez J.M., Bennett M.J., Schlegel B.P., Lewis M., Penning T.M. Comparative anatomy of the aldo-keto reductase superfamily. Biochem. J. 326:1997;625-636.
33. Fischer V., Rodríguez-Gascón A., Heitz F., Tynes R., Hauck C., Cohen D., Vickers A.E.M. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A: implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab. Dispos. 26:1998;802-811.
34. Takanashi S., Bachur N.R. Adriamycin metabolism in man: evidence from urinary metabolites. Drug Metab. Dispos. 4:1976;79-87.
35. Porter S.J., Somogyi A.A., White J.M. Kinetics and inhibition of the formation of 6-naltrexol from naltrexone in human liver cytosol. Br. J. Clin. Pharmacol. 50:2000;465-471.
36. Ainslie G.R. Jr., Shill J.P., Neet K.E. Transients and cooperativity. J. Biol. Chem. 247:1972;7088-7096.
37. Shou M., Lin Y., Lu P., Tang C., Mei Q., Cui D., Tang W., Ngui J.S., Lin C.C., Singh R., Wong B.K., Yergey J.A., Lin J.H., Pearson P.G., Baillie T.A., Rodrigues A.D., Rushmore T.H. Enzyme kinetics of cytochrome P450-mediated reactions. Curr. Drug Metab. 2:2001;17-36.
38. Ekins S., Ring B.J., Binkley S.N., Hall S.D., Wrighton S.A. Autoactivation and activation of the cytochrome P450s. Int. J. Clin. Pharm. Ther. 36:1998;642-651.
39. Maser E., Friebertshäuser J., Völker B. Purification, characterization and NNK carbonyl reductase activities of 11β- hydroxysteroid dehydrogenase type I from human liver: enzyme cooperativity and significance in the detoxification of a tobacco-derived carcinogen. Chem. Biol. Interact. 143-144:2003;435-448.
40. Pais G.C.G., Zhang X., Marchand C., Neamati N., Cowansage K., Svarovskaia E.S., Pathak V.K., Tang Y., Nicklaus M., Pommier Y., Burke T.R. Jr. Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. J. Med. Chem. 45:2002;3184-3194.
41. Marchand C., Johnson A.A., Karki R.G., Pais G.C.G., Zhang X., Cowansage K., Patel T.A., Nicklaus M.C., Burke T.R. Jr., Pommier Y. Metal-dependent inhibition of HIV-1 integrase by β-diketo acids and resistance of the soluble double mutant (F185K/C280S). Mol. Pharmacol. 64:2003;600-609.
42. Grobler J.A., Stillmock K., Hu B., Witmer M., Felock P., Espeseth A.S., Wolfe A., Egbertson M., Bourgeois M., Melamed J., Wai J.S., Young S., Vacca J., Hazuda D.J. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. U.S.A. 99:2002;6661-6666.
43. Shaw-Reid C.A., Munshi V., Graham P., Wolfe A., Witmer M., Danzeisen R., Olsen D.B., Carroll S.S., Embrey M., Wai J.S., Miller M.D., Cole J.L., Hazuda D.J. Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid. J. Biol. Chem. 278:2003;2777-2780.